IsoTis' 4th-qtr net loss widens to $4.3M
USA-based biosurgery company IsoTis says that its loss from operations for the fourth quarter of 2006 widened to $4.3 million from $2.7 million for the comparable period last year, as net loss reached $6.6 million, or $0.09 per diluted share, versus $1.4 million, or $0.02 per diluted share.
However, the Irvine, California-headquartered firm noted that its revenue during the period totaled $9.9 million, a 15% increase over fourth-quarter 2005. IsoTis says that its key highlights last year included: a US patent award for Accell technology; the sale of dental assets to Keystone Dental Inc for $7.4 million; a $5.0 million credit line is secured from SVB Silicon Valley Bank; and a private label agreement with Alphatec Spine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze